Latest News About Mifepristone

Updated 2026-05-21 05:06

I don’t have live access to current news sources in this moment, but I can summarize recent context and indicate where to check for the latest updates on mifepristone.

Core answer

There has been ongoing federal review and legal activity around mifepristone in 2024–2026, including FDA safety data reviews, REMS discussions, and court rulings that have at times affected access. For the very latest developments, please consult major outlets’ health desks or official FDA statements.

Recent context to guide your search

FDA reviews and safety assessments: In 2024–2025, U.S. health leaders signaled ongoing reviews of mifepristone safety data and dispensing conditions, with questions about access and how the drug is used in practice. Look for statements from the FDA and HHS, and coverage by CBS News, CNN, and Health outlets for direct quotes and timeline updates.[1][6][9]
Legal and policy developments: There were publications noting court orders and state-level actions affecting REMS or distribution, and reports discussing how these rulings interact with nationwide access, including potential restrictions or protections for ongoing use in miscarriage management.[2][4][5][7]
Public-health briefings and expert analysis: Medical associations and health-news programs have tracked how regulatory changes might influence telemedicine access, prescribing practices, and patient choice, with updates posted by AMA, CNN, and KFF Health News outlets.[7][9][2]

Where to check for the latest

FDA official updates on mifepristone and REMS program status: fda.gov
Reputable national outlets’ health desks:
- CBS News health section (FDA review updates)
- CNN health coverage on mifepristone and related court rulings
- KFF Health News and Bloomberg Law for policy and regulatory context
Major medical associations’ statements or briefings (AMA, ACOG) for clinical implications

If you’d like, I can:

Narrow down to a specific date range and pull the most relevant articles from major outlets.
Create a quick brief listing key developments and their practical implications for patients in Illinois or Chicago.
Provide a short explainer on what a REMS review could mean for access and how patients can stay informed.

Sources

Federal agencies are studying safety of abortion drug mifepristone, driving new concerns about limits on access

The US Food and Drug Administration is reviewing evidence about the safety and efficacy of mifepristone, one of the drugs used in medication abortion, to investigate how it can be safely dispensed, US…

www.cnn.com

MEMO: What The Latest Mifepristone Stories Reveal About the ...

Bloomberg broke the news that the FDA is delaying the release of its planned review of the mifepristone risk evaluation and mitigation strategy (REMS). The agency’s public line is that it “needs more time.” Bloomberg reporting shows otherwise: the delay is political, timed to push the release until after the midterms.

reproductivefreedomforall.org

Abortion Pill Politics - KFF Health News

A federal court’s decision to restrict availability of the abortion pill mifepristone has launched abortion back into the national spotlight. It’s also raised new questions about the job security of FDA Commissioner Marty Makary. Sandhya Raman of Bloomberg Law, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also, Rovner interviews KFF Health News’ Andrew Jones, who wrote the latest “Bill of the Month."

kffhealthnews.org

FDA to "review the latest data" on mifepristone. What could it mean ...

HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone," but experts say concerns about the abortion pill's safety are misguided.

www.cbsnews.com

Mifepristone, Marburg virus, new COVID variant and RSV ...

The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about news on Mifepristone, new COVID variant and more.

www.ama-assn.org

Mifepristone: Supreme Court Preserves Access to Abortion ...

Access to mifepristone, the widely-used medication for abortion, is hanging in legal limbo. The Department of Justice ordered an appeals court to block the ruling issued by Texas-based Judge Matthew Kacsmaryk that demanded the Food and Drug Administration freeze its approval of the drug. The U.S. Supreme Court has temporarily blocked the decision from the Texas judge as they review the case.